Moderna Cashes in On Omicron

by Martin Armstrong

Moderna, the company that produced its first vaccination under Operation Warp Speed, said it is close to producing a new vaccine for the omicron variant. The news comes just days after the omicron variant was first reported publicly and before the scientific community had a chance to study the variant that has over 32 strains. As a result, Moderna’s stock jumped 14% earlier in the week and has been one of the top performers on the S&P 500 to date.

No one understands the new variant, but there is allegedly a vaccination in production that could be available by early 2022. This should raise many questions. Analysts claim Moderna has the ability to create new mRNA vaccines to combat mutating variants and can begin clinical trials within 60-90 days. Rest assured, all of the vaccine companies are now seeking to cash in on omicron. If these companies do not understand the variant, how can they develop a safe and effective vaccination?

President Biden even said it would take the White House around two weeks to understand omicron. “If people are vaccinated and wear their mask, there’s no need for lockdown,” Biden warned. Biden is lying. There are proven cases of people contracting COVID and various variants despite being fully vaccinated. The US president will deliver a “detailed strategy outlining how we’re going to fight COVID this winter. Not with shutdowns or lockdowns, but with more widespread vaccinations, boosters, testing, and more.” The word “lockdown” puts the markets in a tailspin, and Biden’s handlers have been careful not to mention this keyword in his speeches. Yet, they have made it clear that taking the vaccination could potentially prevent another lockdown. Between the lines is a subtle threat — comply or face the consequences.